Acute coronary syndrome associated with continuous 5-fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma

Introduction: 5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration. A clinical picture consisting of chest pain, sometimes cardiac enzyme elevation, electrocardiogram abnormalities consistent with myocardial ischemia, and normal coronary angiogram associated with 5-FU administration have been infrequently reported. The clinical dilemma is: Which chemotherapy regimen should we use in CRC patients with a previous acute coronary syndrome (ACS) associated with 5-FU? Case Report: We describe the case of a 55-year-old otherwise healthy woman with metastatic colon adenocarcinoma who presented an ACS probably secondary to arterial vasospasm while receiving continuous intravenous 5-FU infusion (mFOLFOX6 regimen). After the ACS, the patient was treated with raltitrexate plus oxaliplatin (TOMOX) and subsequently with irinotecan plus cetuximab with no other cardiac event. Conclusion: The risk of cardiotoxicity associated with 5-FU is low but real. The probable mechanism is arterial vasospasm, as suggested by our case report. Both the use of the TOMOX regimen and irinotecan plus cetuximab seems to be safe regimens to be considered in this clinical scenario. © 2009 Humana Press Inc.

Baixas Doses de 5-fluorouracil aumentam a atividade antitumoral de células dendríticas transfectadas com RNA de células de câncer colorretal

Pós-graduação em Patologia - FMB

Influência do 5-fluorouracil nos tecidos periodontais normais e sobre a evolução da doença periodontal experimental induzida

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Five Percent 5-Fluorouracil in a Cream or for Superficial Peels in the Treatment of Advanced Photoaging of the Forearms: A Randomized Comparative Study

BACKGROUND The antimetabolite 5-fluorouracil (5-FU) is used for topical treatment of actinic keratosis. Overall improvement in the skin is also observed. Additionally, 5-FU was reported to be used for superficial peels.OBJECTIVES To evaluate the efficacy and safety of 5% 5-FU cream compared with peels for photodamaged forearms.METHODS This interventional, randomized, comparative, evaluator-blind study included 32 patients with severe photoaging of forearms. The regimens comprised either application of 5% 5-FU cream everyday for 4 weeks on 1 forearm and 4 weekly peels on the other. Efficacy assessment included: clinical photodamage scores, opinion of patients and investigators, and blind photographic evaluation by independent observers. Skin biopsies were performed for histologic and immunohistochemical analysis. Safety evaluation comprised observation of adverse events.RESULTS Clinical and histologic findings confirmed the benefits of topical 5% 5-FU, in cream or peels, which improved skin appearance and decreased the dermal elastotic material. Immunohistochemistry showed reduced levels of epidermal p53 and increase in the level of procollagen I. Results were maintained after 6 months. Predictable adverse events occurred, with no differences between treatments. Patients reported better tolerability to peels.CONCLUSION Five percent 5-FU cream or peels was safe and effective for the treatment of photodamaged forearms. Decreased epidermal p53 levels and new dermal collagen were confirmed.

Efeito da concentração citostática de 5-fluorouracil sobre a imunogenicidade de células de câncer colorretal murino MC-38

A quimioterapia é o tratamento padrão para pacientes com os mais variados tipos de câncer, (sendo o 5 Fluorouracil -5Fu- a droga de escolha no caso do câncer colorretal) mas ela está associada a efeitos colaterais que podem ser muito severos. A exposição de células tumorais a agentes antineoplásicos, em dose baixa e não citotóxica, pode torná-las mais imunogênicas, enquanto que a exposição de células dendríticas (DC) a esses agentes antineoplásicos pode aumentar sua capacidade de induzir resposta antitumoral in vitro. O objetivo deste estudo é verificar se o tratamento in vitro de células tumorais MC38 com 5-Fu (dose não citotóxica) pode induzir a expressão de moléculas que aumentem suas características imunogênicas, fazendo com que elas sejam mais facilmente identificadas pelo sistema imune. Para isso, camundongos da linhagem C57/Bl-6 foram inoculados subcutaneamente com células MC38 e sete dias depois foram vacinados com DC sensibilizadas com antígenos tumorais obtidos a partir da lise de células MC38 mantidas em cultura e previamente tratadas com 5-Fu, em dose não citotóxica (DC-5Fu), para que a performance das DC sensibilizadas pudesse ser comparada à performance das DC selvagens

Efeito de dose efetiva mínima e dose não tóxica de 5-Fluorouracil e Leucovorina sobre a atividade de células dendríticas humanas e sobre a imunogenicidade de células de câncer colorretal

A quimioterapia antitumoral convencional, baseada na aplicação da dose máxima tolerável de drogas antineoplásicas, está comumente associada com mielossupressão e causa diminuição da viabilidade e número de células dendríticas (DCs), principais células apresentadoras de antígenos (APCs) do sistema imune. Uma alternativa para limitar os efeitos tóxicos desses agentes é a quimioterapia metronômica, baseada na administração das drogas em doses baixas e frequentes que, entre outros aspectos, melhora a eficácia antitumoral pela inibição da angiogênese no sítio do tumor. Estudos prévios do grupo indicam que doses ultrabaixas de determinados agentes antineoplásicos modulam positivamente o estado de ativação e as funções das células dendríticas, sugerindo que a associação entre vacinas de DCs e quimioterapia metronômica possibilitaria a estimulação da resposta imune, ao mesmo tempo em que as células tumorais sofrem o efeito dos agentes antineoplásicos em doses ultrabaixas. Assim, hipotetizamos que o uso de 5-Fluorouracil e Leucovorina, drogas de escolha para o tratamento do câncer colorretal, em dose efetiva mínima ou dose ultrabaixa não tóxica, poderia modular positivamente as DCs humanas e potencializar a imunogenicidade de células tumorais, além de torná-las mais sensíveis à ação de linfócitos T citotóxicos. Desse modo, o presente estudo tem o objetivo de avaliar o efeito in vitro da dose efetiva mínima e dose não tóxica de 5-Fluorouracil e Leucovorina sobre as funções de células dendríticas humanas e sobre a imunogenicidade de células de câncer colorretal humano da linhagem HT-29. Com esse propósito as DCs humanas foram sensibilizadas com lisatos de células tumorais pré tratadas com as doses previamente determinadas das drogas e avaliadas quanto à capacidade de apresentação de antígenos e indução de linfócitos T citotóxicos... (Resumo completo, clicar acesso eletrônico abaixo)

Expression of Vascular Endothelial Growth Factor (VEGF) in Macrophages, Fibroblasts, and Endothelial Cells in Pterygium Treated with 5-Fluorouracil

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Evaluation of the progression and treatment of experimental periodontitis in rats subjected to chemotherapy with 5-fluorouracil

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Influência da quimioterapia com 5-Fluorouracil na osseointegração de implantes instalados em tíbias de ratos: avaliação biomecânica, microtomográfica, histomorfométrica, histoquímica e imunoistoquímica

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Influência da quimioterapia com 5-Fluorouracil na osseointegração de implantes instalados em tíbias de ratos: avaliação biomecânica, microtomográfica, histomorfométrica, histoquímica e imunoistoquímica

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Shape resonance spectra of uracil, 5-fluorouracil, and 5-chlorouracil.

We report on the shape resonance spectra of uracil, 5-fluorouracil, and 5-chlorouracil, as obtained from fixed-nuclei elastic scattering calculations performed with the Schwinger multichannel method with pseudopotentials. Our results are in good agreement with the available electron transmission spectroscopy data, and support the existence of three π* resonances in uracil and 5-fluorouracil. As expected, the anion states are more stable in the substituted molecules than in uracil. Since the stabilization is stronger in 5-chlorouracil, the lowest π* resonance in this system becomes a bound anion state. The present results also support the existence of a low-lying σ ∗ CCl shape resonance in 5- chlorouracil. Exploratory calculations performed at selected C–Cl bond lengths suggest that the σ ∗ CCl resonance could couple to the two lowest π* states, giving rise to a very rich dissociation dynamics. These facts would be compatible with the complex branching of the dissociative electron attachment cross sections, even though we cannot discuss any details of the vibration dynamics based only on the present fixed-nuclei results.

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

The importance of polymorphisms in the dihydropyrimidine dehydrogenase (DPD) gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU) based chemotherapy has been controversially debated. As a key enzyme in the catabolism of 5-FU, DPD is the top candidate for pharmacogenetic studies on 5-FU toxicity, since a reduced DPD activity is thought to result in an increased half-life of the drug, and thus, an increased risk of toxicity. Here, we review the current knowledge on well-known and frequently studied DPYD variants such as the c.1905+1G>A splice site variant, as well as the recent discoveries of important functional variation in the noncoding regions of DPYD. We also outline future directions that are needed to further improve the risk assessment of 5-FU toxicity, in particular with respect to metabolic profiling and in the context of different combination therapeutic regimens, in which 5-FU is used today.

LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients

The chemotherapeutic drug 5-fluorouracil (5-FU) is widely used for treating solid tumors. Response to 5-FU treatment is variable with 10-30% of patients experiencing serious toxicity partly explained by reduced activity of dihydropyrimidine dehydrogenase (DPD). DPD converts endogenous uracil (U) into 5,6-dihydrouracil (UH(2) ), and analogously, 5-FU into 5-fluoro-5,6-dihydrouracil (5-FUH(2) ). Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy. Here, we report the development of a liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of U, UH(2) , 5-FU and 5-FUH(2) in human plasma. Samples were prepared by liquid-liquid extraction with 10:1 ethyl acetate-2-propanol (v/v). The evaporated samples were reconstituted in 0.1% formic acid and 10 μL aliquots were injected into the HPLC system. Analyte separation was achieved on an Atlantis dC(18) column with a mobile phase consisting of 1.0 mm ammonium acetate, 0.5 mm formic acid and 3.3% methanol. Positively ionized analytes were detected by multiple reaction monitoring. The analytical response was linear in the range 0.01-10 μm for U, 0.1-10 μm for UH(2) , 0.1-75 μm for 5-FU and 0.75-75 μm for 5-FUH(2) , covering the expected concentration ranges in plasma. The method was validated following the FDA guidelines and applied to clinical samples obtained from ten 5-FU-treated colorectal cancer patients. The present method merges the analysis of 5-FU pharmacokinetics and DPD activity into a single assay representing a valuable tool to improve the efficacy and safety of 5-FU-based chemotherapy.

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

This study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU.

A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy

Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe toxicity. Recently described genetic variation in dihydropyrimidine dehydrogenase (DPYD) has been shown to be a major predictor of 5FU toxicity. Here, we describe a new genotyping assay for routine clinical use that covers all the major DPYD risk variants.